Skip to main
GILD

Gilead Sciences (GILD) Stock Forecast & Price Target

Gilead Sciences (GILD) Analyst Ratings

Based on 16 analyst ratings
Buy
Strong Buy 38%
Buy 50%
Hold 13%
Sell 0%
Strong Sell 0%

Bulls say

Gilead Sciences is poised for a positive financial outlook, with revenue estimates for Trodelvy being raised ahead of its anticipated approval and launch in the second half of 2026, indicating strong market confidence in its oncology pipeline. The company has achieved a significant milestone by hitting its 90% payer coverage goal ahead of schedule, enhancing its revenue potential from the oncology segment, which is critical for diversification amid competitive challenges. Additionally, the robust growth in Gilead's HIV franchise, alongside disciplined operational expenditures and improved operating margins, supports a favorable revenue growth trajectory projected at approximately 4-6% year-on-year for 2026, bolstered by innovations within both the HIV and oncology portfolios.

Bears say

Gilead Sciences has exhibited a concerning trend with its financial performance, particularly highlighted by the substantial reduction in fiscal year 2025 revenue guidance for Veklury from $1.4 billion to $1.0 billion, and an expected decline to $600 million in 2026. The cell therapy segment is also facing challenges, with a reported revenue of $458 million reflecting a 6% year-over-year decrease, and projected to decline further by 10% in 2026 due to ongoing competitive pressures. Additionally, anticipated policy-related headwinds and a $300 million drop in Veklury sales will likely exacerbate revenue weaknesses, diminishing the overall significance of Veklury's contributions to total revenues as they continue to trend downward.

Gilead Sciences (GILD) has been analyzed by 16 analysts, with a consensus rating of Buy. 38% of analysts recommend a Strong Buy, 50% recommend Buy, 13% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Gilead Sciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Gilead Sciences (GILD) Forecast

Analysts have given Gilead Sciences (GILD) a Buy based on their latest research and market trends.

According to 16 analysts, Gilead Sciences (GILD) has a Buy consensus rating as of Apr 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $150.88, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $150.88, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Gilead Sciences (GILD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.